Drugs / [177Lu]Lu-DOTA-EB-RGD2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07655869 | Jun → Dec 2026 expected | IDH-wildtype glioblastoma | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [177Lu]Lu-DOTA-EB-RGD2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07655869 ↗ |
| Modality | Peptide | “A long-circulating radiolabeled peptide targeting integrin αvβ3.” NCT07655869 ↗ |
| Route | Intravenous | “It is administered intravenously (20-30 min infusion) or locoregionally via Ommaya reservoir directly into the tumor cavity.” NCT07655869 ↗ |
| Route | Other | “It is administered intravenously (20-30 min infusion) or locoregionally via Ommaya reservoir directly into the tumor cavity.” NCT07655869 ↗ |